Fola Injection contains L-Ornithine L-Aspartate (5gm), a compound used primarily to support liver function and treat conditions associated with elevated blood ammonia levels, such as hepatic encephalopathy. L-Ornithine L-Aspartate works by enhancing the urea cycle, facilitating the detoxification of ammonia in the liver, thereby reducing neurotoxic effects and improving mental status in affected patients. This injection is typically administered intravenously or intramuscularly under medical supervision, ensuring rapid absorption and efficacy. It is indicated for patients with liver cirrhosis, chronic liver diseases, or acute liver failure where ammonia accumulation poses a significant risk. Fola Injection may also be used as an adjunct therapy in managing hepatic coma and other metabolic disorders involving hyperammonemia. The dosage and duration of treatment depend on the severity of the condition and the patient’s response, and it should be used cautiously in individuals with known hypersensitivity to the active ingredients. Common side effects are generally mild but may include local injection site reactions or gastrointestinal disturbances. Overall, Fola Injection is a valuable therapeutic agent in improving liver detoxification processes and enhancing patient outcomes in hepatic dysfunction.